The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06124976
Recruitment Status : Recruiting
First Posted : November 9, 2023
Last Update Posted : April 1, 2024
Sponsor:
Information provided by (Responsible Party):
Peter Black, University of British Columbia

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor.

The main questions this study aims to answer are:

  1. Can ST-02 effectively eradicate UTUC by 3 months?
  2. Is ST-02 safe for patients with UTUC?

Participants in this study will receive ST-02, a new formulation with gemcitabine once weekly for six weeks. Gemcitabine is known to be an effective drug in treating urothelial carcinoma. This new formulation will be instilled directly into the upper urinary tract (renal pelvis) and will allow the chemotherapeutic to work locally for an extended period of time. The administration process will be retrograde (via a small catheter inserted up into the kidney, under anesthesia) or antegrade (via a nephrostomy, in the clinic) once weekly for six weeks. Safety and efficacy will be monitored for up to a year after the initial response assessment.


Condition or disease Intervention/treatment Phase
Urothelial Carcinoma of the Renal Pelvis and Ureter Transitional Cell Cancer of the Renal Pelvis and Ureter Drug: ST-02 Phase 2 Phase 3

Detailed Description:

This study is a prospective, multicenter, single-arm, open-label clinical trial assessing the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to chemo-ablate low-grade urothelial carcinoma of the upper urinary tract.

Participants with biopsy confirmed low-grade (LG) upper tract urothelial carcinoma (UTUC) and a tumor of 5 to 15 mm will receive 6 weekly instillations of ST-02.

The primary objective is to evaluate complete response (CR) at 3 months from the first instillation during the primary tumor evaluation (PTE) visit. This is done by ureteroscopy, and cytology, with or without biopsy if a tumor remains. If the participant presents as a CR, they will receive their first maintenance instillation of ST-02. Endoscopic monitoring of the upper tract with ureteroscopy for responders will be performed every 3 months for up to 12 months after CR, and the patient will receive a single instillation of ST-02 if no recurrence is noted each time.

Participants who do not have a CR will be treated by their physician with the standard of care, such as biopsy and laser ablation, and with any additional surgical procedure or treatment as deemed necessary by the Principal Investigator (PI).

The first stage of the trial will enroll 30 patients. If there are 8 or fewer CR among these 30 participants, the study will be stopped. Otherwise, an additional 40 participants will be accrued into phase 3, resulting in a total sample size of 70.

The durability of response, event-free survival, safety, and other outcomes will also be measured.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2/3 Multicenter Trial Evaluating the Safety and Efficacy of ST-02 (Mucoadhesive Gemcitabine Suspension) on Ablation of Urothelial Carcinomas in the Upper Urinary Tract
Estimated Study Start Date : March 2024
Estimated Primary Completion Date : April 2026
Estimated Study Completion Date : April 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ST-02
ST-02 is a new gemcitabine formulation for instillation into the upper urinary tract. Eligible participants will be enrolled and receive ST-02 once weekly for six weeks in a retrograde or antegrade fashion at the discretion of the treating urologist.
 Drug: ST-02
ST-02 drug instillation into the upper urinary tract (renal pelvis)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Complete Response (CR) rate at the Primary Tumor Evaluation (PTE) visit [ Time Frame: 3 months ]
    To evaluate the tumor ablative effect (CR after 3 months) of six instillations of ST-02 in the upper urinary tract of participants with UTUC.


Secondary Outcome Measures :
  1. Durable efficacy [ Time Frame: 12 months after CR ]
    To evaluate the durability of tumor ablative effect 12 months after CR in participants who demonstrated complete response at 3 months after instillation of six doses of ST-02

  2. Objective Response Rate (ORR) [ Time Frame: 3 months ]
    To evaluate the objective response rate after treatment with ST-02, defined as proportion of participants with Complete Response (CR) or Partial Response (PR) at the PTE Visit

  3. Event-Free Survival (EFS) [ Time Frame: 15 months ]
    To evaluate the event-free survival after treatment with ST-02

  4. Number of adverse event [ Time Frame: 15 months ]
    To evaluate the safety and tolerability of instillation of ST-02 in participants with UTUC

  5. Peak Plasma Concentration (Cmax) [ Time Frame: 24 hours ]
    To assess the peak concentration of gemcitabine in urine and plasma at 0, 1, 2, 4 and 24 hours after instillation (10 patients, phase 2 only)

  6. Pharmacokinetics (Tmax) [ Time Frame: 24 hours ]
    To assess the time to maximal concentration of gemcitabine in urine and plasma at 0, 1, 2, 4 and 24 hours after instillation (10 patients, phase 2 only)

  7. Rate of invasive surgery [ Time Frame: 15 months ]
    To evaluate the rate of nephroureterectomy following instillation of ST-02

  8. Clinical impact of PR in not endoscopically resectable UTUC [ Time Frame: 3 months ]
    To evaluate the proportion of participants with PR whose tumors were considered not endoscopically resectable at baseline but are endoscopically resectable after treatment with ST-02


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult (≥ 18 years) male or female
  • Primary or recurrent low-grade (LG), noninvasive (Ta) Upper Tract Urothelial Carcinoma (UTUC) in the renal pelvis, infundibulum, and/or calyces, based on ureteroscopy, biopsy and cytology performed within 8 weeks prior to the Screening Visit
  • At least 1 measurable papillary tumor measuring 5-15 mm
  • Low grade tumor(s) in the ipsilateral ureter. Every attempt should be made to ablate this tumor completely, but residual ipsilateral ureteral tumor is not an exclusion criterion.
  • Prior fully ablated low grade bladder tumor(s), without the need for intravesical therapy except for single-dose chemotherapy
  • A life expectancy of greater than 12 months
  • No active untreated urinary tract infection (UTI) as confirmed by urine culture or urinalysis
  • Women of Child bearing potential (WoCBP) and Males who have a WoCBP partner require a negative pregnancy test at the Screening visit and must use two acceptable contraceptives methods until six months post-treatment
  • All sexually active males must agree to use a condom during intercourse, for at least 48 h after each instillation

Exclusion Criteria:

  • Have received Bacillus Calmette - Guerin (BCG) treatment for UTUC within 6 weeks prior to Visit 1
  • Pregnant (positive urine pregnancy test), planning pregnancy during trial, breast-feeding, or of childbearing potential without reliable contraception
  • Unresolved infection requiring active treatment with systemic antimicrobial drugs
  • History of high-grade non-muscle invasive bladder cancer within the past 6 months
  • History of muscle-invasive bladder cancer during the past 2 years
  • Actively being treated or intend to be treated with intravesical or systemic chemotherapy during the duration of the trial
  • Urinary obstruction in the ipsilateral Upper Urinary Tract (UUT)
  • Any contraindicated to gemcitabine or sensitivity to gemcitabine or any of the ST-02 ingredients
  • Currently receiving another investigational agent or involved in a clinical trial with an investigational product within the past 30 days prior to Visit 1
  • Active hepatitis B (chronic or acute) or active hepatitis C infection
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06124976


Contacts
Layout table for location contacts
Contact: Dasa Durkotova 236 869 3437 ddurkotova@prostatecentre.com

Locations
Layout table for location information
Canada
Vancouver Prostate Centre Recruiting
Vancouver, Canada
Contact: Genevive Moreau         
Principal Investigator: Peter Black         
Sub-Investigator: Marie-Pier Marie-Pier St-Laurent         
Sub-Investigator: Miles Mannas         
Sponsors and Collaborators
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: Peter Black, Dr. Vancouver Prostate Centre
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Peter Black, Professor, University of British Columbia
ClinicalTrials.gov Identifier: NCT06124976    
Other Study ID Numbers: H23-02476
First Posted: November 9, 2023    Key Record Dates
Last Update Posted: April 1, 2024
Last Verified: March 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms